

Lifeloc Technologies
Annual Shareholders Meeting
May 10, 2021



Committed to safer roads and
workplaces worldwide

1

Welcome Shareholders

- Agenda
- Shareholder Votes per Proxy Statement
- State of the Company

2

Lifeloc Technologies

Safe Harbor Agreement

This presentation contains forward-looking statements which reflect management's expectations regarding Lifeloc's future growth, results of operations, performance (both operational and financial) and business prospects and opportunities. Where possible words such as "plans," "expects" or "does not expect," "budget," "forecasts," "anticipates" or "does not anticipate," "believes," "intends" and similar expressions or statements that certain actions, events or results "may," "could," "would," "might" or "will" be taken, occur or be achieved, have been used to identify these forward-looking statements. Although the forward-looking statements contained in this presentation reflect management's current assumptions based upon information currently available to management and based upon that which management believes to be reasonable assumptions, Lifeloc cannot be certain that actual results will be consistent with these forward looking statements. Forward-looking statements necessarily involve significant known and unknown risks, assumptions and uncertainties that may cause Lifeloc's actual results, performance, prospects and opportunities in future periods to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things: international and domestic operations, customer demand, regulatory matters credit and customer concentration; competition; rapid technological change; product liability claims; intellectual property; use of non-GAAP financial measures; significant shareholder; supply arrangements; and dependence upon key management personnel and executives. For more details, please see the "Risk Factors" section of our SEC filing.

Although Lifeloc has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Accordingly, as noted above, you should not place undue reliance on forward-looking statements. These forward-looking statements are made as of the date of this presentation and, except as required by law, Lifeloc assumes no obligation to update or revise them to reflect new events or circumstances.

3

Lifeloc Today

- Installed base in over 65 countries.
- Global penetration in both workplace testing and law enforcement
- Core Business is usually cash flow positive
- \$6.36 million sales, 2020
- Equivalent of 33 full time employees
- Big growth opportunities to address are offender monitoring and real time drug testing

4

COVID-19 Pandemic

Pandemic dominated company agenda in 2020, with significant demand decline

- Hiring freeze implemented January 2020, since removed
- Reduced workplace density / remote where possible
- Participation in PPP, both rounds
- Strong balance sheet and PPP allowed careful reduction in force without compromising development capacity
- Sales now trending upward

5

2020 Income Statement

Income Statement	2020	2019
Revenue	\$ 6,356,702	\$ 8,751,823
Gross Profit	\$ 2,180,546	\$ 3,936,003
Gross Margin	34.3%	45.0%
R&D	\$ 1,007,297	\$ 1,038,227
Sales	\$ 1,074,249	\$ 1,240,773
General and Admin	\$ 1,254,503	\$ 1,175,788
Pretax Income	\$(1,197,338)	\$ 687,362
Net Income	\$ (921,930)	\$ 625,826

6

6

Return to Growth

Immediate Contributors

- EasyCal® G2
- New Platform LX9 and LT7
- R.A.D.A.R.® 200

Ultimate Target

- Lifeloc seeks to grow and exceed \$100 million
- With real time drug testing via SpinDx

EasyCal® and R.A.D.A.R.® are registered trademarks of Lifeloc Technologies

7

EasyCal® G2



Calibrates all Lifeloc Professional models, including R.A.D.A.R.® 200 model

Sales up 71% year to date through April

Builds a moat for the company

8

New Platform LX9 and LT7



The image shows a black handheld device labeled LX9. It has a screen displaying "#12 09:14" and "AUTO TEST" with a helmet icon. A white breathalyzer tube is attached to the top. The Lifelec logo is at the bottom.

- Registrations: US DOT, SAI Global (1997 and 2019 standards)
- New firmware release this week (robustness and add features requested European LE agencies)
- Test down to -10°C
- Ambidextrous
- GPS, WiFi, Bluetooth
- Customization through configuration files

9

New Platform LX9 and LT7



The image shows an orange and black handheld device labeled LT7. It has a screen displaying "#1 09:49" and "AUTO TEST" with a helmet icon. A white breathalyzer tube is attached to the top. The Lifelec logo is at the bottom.

- Sold in:
 - Arizona
 - Australia
 - Bolivia
 - California
 - Finland
 - India
 - Indonesia
 - Malaysia
 - Mexico
 - New Zealand
 - Poland
 - Tonga

10

R.A.D.A.R.® Opportunity

- R.A.D.A.R. 200 model is in field testing with key customers
- New model has updated communication, improved mechanical reliability and GPS accuracy
- R.A.D.A.R. business model shifts to recurring revenue stream through leasing and monitoring fees
- Model update required reporting system upgrades also
 - Enrollment application
 - New client wizard
 - Client summary page
 - Automated calibration



11

11

R.A.D.A.R.® New Client Wizard

Lifeloc TECHNOLOGIES R.A.D.A.R.® Welcome Erik.Barca@Lifeloc.com[Log Out]
Time Zone Mountain Standard Time[My Account]

Dashboard Case Files Inventory Dropdown *

NEW CLIENT WIZARD

Details Schedule Notifications Assign Device

Case Details DEMOGRAPHIC AND OTHER EMPLOYER CONTACT EMERGENCY CONTACT

Details Contact

First Name * Middle Name Last Name *

test test test

Case Number * Alt Case Number State ID Number *

Case# 1234-111 Case# 2 State ID

Supervision Level Time Zone * Agent

Level 01 (UTC-07:00) Mountain Time (US & Canada) Choose Agent...

Next

12

12

R.A.D.A.R.® New Client Wizard

Welcome Erik.Barcza@Lifeloc.com [Log Out]
Time Zone Mountain Standard Time [My Account]

Dashboard Case Files Inventory Dropdown ▾

NEW CLIENT WIZARD

Details Schedule Notifications Assign Device

Schedule
Schedule Name:
Day Schedule
 Mon Tues Weds Thurs Fri Sat Sun

Number of Tests:

Start Time:

End Time:

Schedule
Schedule Name:
Day Schedule
 Mon Tues Weds Thurs Fri Sat Sun

Number of Tests:

Start Time:

End Time:

Remove

[Add Another Schedule](#)

[Previous](#)

[Next](#)

13

R.A.D.A.R.® New Client Wizard

Welcome Erik.Barcza@Lifeloc.com [Log Out]
Time Zone Mountain Standard Time [My Account]

Dashboard Case Files Inventory Dropdown ▾

NEW CLIENT WIZARD

Details Schedule Notifications Assign Device

Notification
Message To:
Client Text
Phone/Email:

Message Type:
Next Test
Person Name:

Comm Type:

Notification
Message To:
Client Text
Phone/Email:

Message Type:
Alcohol
Person Name:

Comm Type:

Client/Offender communication cannot be created for the following: Alcohol, ID Failed, and ID Confirmed.

[Add Another Notification](#)

[Previous](#)

[Next](#)

14

R.A.D.A.R.® New Client Wizard

The screenshot displays the 'NEW CLIENT WIZARD' interface. At the top, the Lifeloc Technologies logo and 'R.A.D.A.R.®' are visible. The user is logged in as Erik.Barca@Lifeloc.com. A navigation bar includes 'Dashboard', 'Case Files', 'Inventory', and a 'Dropdown' menu. The wizard progress bar shows four steps: 'Details', 'Schedule', 'Notifications', and 'Assign Device'. The 'Assign Device' step is highlighted. Below the progress bar, the 'Assign Device to Case:' section features a dropdown menu with the selected item '08YV3IS000000014 Fuel Cell Expires(6/3/2015 12:00:00 AM)'. 'Previous' and 'Submit' buttons are located at the bottom right of the wizard area.

15


Drugs of Abuse

- The DOA market remains our best opportunity for the growth that we seek.
- The drug testing needs are enormous and growing.
- Growing legalization only makes the need stronger. Legalization is not permission to drive or work impaired.

16


SpinDx Development

- SpinDx methodology determined to be:
 - most sensitive (5ng/ml)
 - discriminating
 - portable
- Leverage the Lifelog capability to design and manufacture rugged portable testers
- Lifelog has existing channel to both Law Enforcement and Workplace markets



17

SpinDx Methodology




- Sample for analysis introduced to disc with reagents for analysis
- Ultracentrifugation concentrates unconsumed antibody with fluorotag in disc analysis tip
- Presence of drug prevents antibody with fluorotag from traveling to analysis tip, proportionately reducing the signal

18

SpinDx Development Status


- Lifeloc designed prototype with GUI being built.
- Laboratory space expanding with disc development equipment coming in house
- Dedicated staff in place with SpinDx commercialization as primary objective
- All team members granted full vested options
- Bonus structure in place to accelerate first commercial sale



19

SpinDx Next Steps

- Must put a stake in the ground showing clear test results
- First product release will be a SpinDx reader with liquid (saliva) analysis disc
- Breath analysis disc will follow as soon as possible



20

Lifeloc Growth Summary

New products (EasyCal G2, LX9, LT7, and R.A.D.A.R. 200) will drive immediate growth.

These will fund the ultimate growth target of real time drug testing without major shareholder dilution.

21

Thank you Lifeloc shareholders for
your continued support

22